Hemcheck´s Newsletter - September 2020

Welcome to the September newsletter from Hemcheck

We have in September continued our work with high energy on multiple fronts. We are for example running and planning user tests as well as holding dialogues with potential customers and partners despite the pandemic. We are also working on developing the new product in blood gas and conducting other development activities.

In this newsletter you can read more about the Medtech Innovation Briefing (MIB) on our technology made by NICE.

You can also read about the extension of the evaluation agreement with Hemakim and some more details on our participation in the Bridgehead program.

We look forward to the rest of 2020 and the opportunities that lie ahead.

Enjoy the reading!
Joen Averstad, CEO

UK NICE published a Medtech Innovation Briefing on Hemcheck's point of care hemolysis detection technology

The UK National Institute for Health and Care Excellence (NICE) has issued a Medtech Innovation Briefing (MIB) on Hemcheck’s novel point of care hemolysis detection technology. The briefing reports that the technology is novel and that there can be several benefits for patients and the system, such as reducing delays to correct and final blood results, speeding up clinical decisions and avoiding false conclusions related to blood gas analysis.

A MIB does not contain any recommendations, but its typically positive in customer dialogues in the UK that a MIB has been published. There are possibilities to get recommended by NICE, however this typically requires locally developed clinical evidence which is a natural next step to work on for Hemcheck.

Click here to read more about NICE MIBs

Click here to read more information from Hemcheck on this topic

Work has been started within the Bridgehead program with focus on the French and Dutch markets

Hemcheck initiated the work within the Bridgehead program during September together with our local partners Medscaler and Medicen. Part of the work is developing a better understanding of the local markets which is one of the first areas of work that has been started. Contacts with local potential customers are also initiated and first meetings have been set up.

-We can already see the value of having local partners with local networks, which we hope will lead to local trials and new customers. However, we are early into this program and a lot of work remains, says Joen Averstad.

Click here to read more about Medscaler

Click here to read more about Medicen
logo medicen

Evaluation agreement with Hemakim regarding potential distribution in Turkey extended to the end of 2020

The evaluation agreement that is now extended was formed to evaluate the collaboration and market opportunity. After the extended evaluation period, the agreement can be extended into a distribution agreement with the same terms as earlier communicated.

The reason for the extension is that the pandemic has delayed some of the evaluation activities that were planned and we now allow for more time to complete those activities, which is good for both parties.

Read more here
Contact Us
Hemcheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad